Company Overview - Sanofi Guojian is primarily engaged in the research, production, and sales of antibody drugs, with its main business revenue composition being 75.24% from product sales, 15.37% from commissioned processing services, 7.94% from licensing services, and 1.44% from leasing services [1] - The company was established on January 25, 2002, and was listed on July 22, 2020 [1] Financial Performance - For the first half of 2025, Sanofi Guojian achieved operating revenue of 642 million yuan, representing a year-on-year growth of 7.61%, and a net profit attributable to shareholders of 190 million yuan, which is a year-on-year increase of 46.96% [2] - Since its A-share listing, the company has distributed a total of 107 million yuan in dividends [3] Stock Market Activity - As of September 16, the stock price of Sanofi Guojian was 53.61 yuan per share, with a market capitalization of 33.066 billion yuan [1] - The stock has seen a year-to-date increase of 151.34%, but has experienced a decline of 4.05% over the last five trading days [1] - The company has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on May 27, where it recorded a net purchase of 657,000 yuan [1] Shareholder Information - As of June 30, 2025, the number of shareholders of Sanofi Guojian was 12,800, an increase of 19.01% from the previous period, with an average of 48,028 circulating shares per person, a decrease of 15.97% [2] - Notable new institutional shareholders include ICBC Frontier Medical Stock A and China Europe Medical Health Mixed A, holding 3.199 million shares and 3.055 million shares respectively [3]

国浩律师(上海)事务所 法律意见书 国浩律师(上海)事务所 关于三生国健药业(上海)股份有限公司 2025 年第五次临时股东大会的 法律意见书 致:三生国健药业(上海)股份有限公司 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民 共和国证券法》（以下简称"《证券法》"）和中国证券监督管理委员会《上市 公司股东会规则》（以下简称"《股东会规则》"）的规定,国浩律师(上海) 事务所接受三生国健药业(上海)股份有限公司(以下简称"公司")董事会的 聘请,指派律师现场见证了公司于 2025年9月 15 目 10:00 起在中国(上海)自由 贸易试验区李冰路 399 号公司会议室召开的公司 2025年第五次临时股东大会,并 依据有关法律、法规、规范性文件的规定以及《三生国健药业〈上海）股份有限 公司章程》（以下简称"《公司章程》"）的规定,对本次股东大会的召集、召 开程序、出席人员资格、大会表决程序等事宜进行了审查,现发表法律意见如下: 一、股东大会的召集、召开程序 公司董事会已于 2025 年 8 月 30 日在中国证监会指定信息披露网站上向公司 股东发出了召开 2025 年第五次临时股东大会的会 ...

证券代码：688336 证券简称：三生国健 公告编号：2025-054 三生国健药业（上海）股份有限公司 2025年第五次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 9 月 15 日 （二） 股东大会召开的地点：中国（上海）自由贸易试验区李冰 路 399 号公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的 优先股股东及其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 121 | | --- | --- | | 普通股股东人数 | 121 | | 2、出席会议的股东所持有的表决权数量 | 530,461,393 | | 普通股股东所持有表决权数量 | 530,461,393 | | 3、出席会议的股东所持有表决权数量占公司表决权 | 86.0041 | | --- | --- | | 数量的比例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的 | 86.0041 | | 比例（%） ...

证券代码：688336 证券简称：三生国健 三生国健药业（上海）股份有限公司 2025 年第五次临时股东大会会议资料 二〇二五年九月 1 目录 | 2025 | 年第五次临时股东大会会议须知 | 3 | | --- | --- | --- | | 2025 | 年第五次临时股东大会会议议程 | 6 | | 2025 | 年第五次临时股东大会会议议案 | 9 | | 议案 | 1、《关于公司<2025 年中期利润分配方案>的议案》 | 9 | | 议案 | 2、《关于取消监事会、废止<监事会议事规则>并修订<公司章程>的议案》 | ... 10 | | 议案 | 3、《关于修订和制定部分公司治理制度的议案》 | 11 | | 议案 | 4、《关于选举第五届董事会独立董事的议案》 | 13 | 2 三生国健药业（上海）股份有限公司 2025 年第五次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事 效率，保证大会的顺利进行，根据《中华人民共和国公司法》《中华 人民共和国证券法》《上市公司股东会规则》以及《三生国健药业（上 海）股份有限公司章程》（以下简称"《公司章程》"）、《三生国 ...

Group 1 - The core viewpoint of the news is that Sangfor Health experienced a decline in stock price, dropping by 5.02% to 58.51 CNY per share, with a trading volume of 286 million CNY and a turnover rate of 0.78%, resulting in a total market capitalization of 36.088 billion CNY [1] - Sangfor Health, established on January 25, 2002, and listed on July 22, 2020, is primarily engaged in the research, production, and sales of antibody drugs. The revenue composition includes 75.24% from product sales, 15.37% from commissioned processing services, 7.94% from licensing services, and 1.44% from leasing services [1] Group 2 - From the perspective of the top ten circulating shareholders, a fund under ICBC Credit Suisse, specifically the ICBC Credit Suisse Frontier Medical Stock A (001717), entered the top ten shareholders in the second quarter, holding 3.199 million shares, which accounts for 0.52% of the circulating shares. The estimated floating loss today is approximately 9.885 million CNY [2] - The ICBC Credit Suisse Frontier Medical Stock A (001717) was established on February 3, 2016, with a latest scale of 9.33 billion CNY. Year-to-date returns are 42.65%, ranking 506 out of 4222 in its category; the one-year return is 46.43%, ranking 1914 out of 3795; and since inception, the return is 275.3% [2] - The fund manager of ICBC Credit Suisse Frontier Medical Stock A is Zhao Bei, who has a cumulative tenure of 10 years and 298 days, with a total fund asset size of 16.425 billion CNY. The best fund return during Zhao's tenure is 275.3%, while the worst return is -24.35% [2]

Core Viewpoint - Sanofi Guojian reported a revenue of 642 million yuan for the first half of 2025, marking a year-on-year growth of 7.61%, and a net profit of 190 million yuan, reflecting a significant increase of 46.96% [1] Group 1: Financial Performance - The company achieved a revenue of 642 million yuan in the first half of 2025, which is a 7.61% increase compared to the previous year [1] - The net profit for the same period was 190 million yuan, showing a substantial growth of 46.96% year-on-year [1] Group 2: Research and Development Focus - Sanofi Guojian is one of the first Chinese biopharmaceutical companies focusing on innovative antibody drug research, with 13 innovative drugs in various stages of development [1] - The company emphasizes a strategic focus on autoimmune diseases as the next key area after oncology, aiming to build a competitive advantage through differentiation, precision, and platform-based strategies [2] Group 3: Strategic Partnerships and Licensing - In May, Sanofi Guojian entered a global licensing agreement with Pfizer for the SSGJ-707 (PD-1/VEGF dual antibody), achieving a record upfront payment exceeding 6 billion USD, with a total transaction value over 60 billion USD [1] - The profit distribution from this licensing agreement will be shared between Sanofi Guojian and its partners at a ratio of 30% and 70% respectively [1] Group 4: Clinical Development and Regulatory Environment - The company has accelerated its clinical project progress due to internal efficiencies and a focused strategy on autoimmune diseases, supported by a highly experienced clinical team [3] - Recent regulatory reforms in China have improved the clinical trial approval process, enhancing overall efficiency for innovative drug development [3] - The company’s product 608 (IL-17) has shown promising results with low relapse rates and immunogenicity, while the 611 (IL-4Rα) project is expected to submit an NDA application by 2026 based on positive mid-term data [3]

Core Insights - The company is firmly focused on the autoimmune disease sector as the next major growth area following oncology, emphasizing a clear strategy, differentiated positioning, efficient execution, and open collaboration as key to success [1] - The company employs a three-pronged strategy of "frontier biological insights," a differentiated technology platform, and precise clinical development to drive innovation and clinical advancement [1] Product Development - The company's product 608 (IL-17) demonstrates significant differentiation with advantages such as lower dosing frequency and superior efficacy, showing a PASI100 response rate that outperforms competitors at both 12 weeks and 52 weeks [2] - Current data indicates that product 608 has a low relapse rate, low immunogenicity, and a low incidence of anti-drug antibodies (ADA) with no neutralizing antibodies detected [2] - The company anticipates submitting a New Drug Application (NDA) for product 611 (IL-4Rα) in 2026, as mid-term data from its Phase III clinical study for adult atopic dermatitis shows positive results [2]

Core Viewpoint - The biopharmaceutical sector experienced a significant increase of 3.06% on September 5, with Sanofi leading the gains [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3812.51, up 1.24% [1] - The Shenzhen Component Index closed at 12590.56, up 3.89% [1] Group 2: Individual Stock Performance - Sanofi (688336) closed at 61.60, with a rise of 11.80% and a trading volume of 165,400 shares, totaling a transaction value of 9.62 billion [1] - Changchun High-tech (000661) closed at 128.00, increasing by 7.53% with a trading volume of 270,100 shares [1] - Junshi Biosciences (688180) closed at 48.00, up 7.38% with a trading volume of 252,900 shares, totaling 1.17 billion [1] - Tibet Pharmaceutical (600211) closed at 50.48, rising by 7.13% with a trading volume of 220,200 shares, totaling 1.08 billion [1] - Other notable stocks include: - Rongan Bio (688331) at 92.17, up 4.32% [1] - Kexing Pharmaceutical (688136) at 42.27, up 4.14% [1] Group 3: Capital Flow - The biopharmaceutical sector saw a net inflow of 231 million from institutional investors, while retail investors experienced a net outflow of 25.77 million [1]

Core Insights - Sangfor Technologies saw a 5.25% increase in stock price, reaching 57.99 CNY per share, with a trading volume of 444 million CNY and a turnover rate of 1.30%, resulting in a total market capitalization of 35.767 billion CNY [1] Company Overview - Sangfor Technologies was established on January 25, 2002, and went public on July 22, 2020. The company is located in the China (Shanghai) Free Trade Zone [1] - The main business activities of Sangfor Technologies include research, production, and sales of antibody drugs. The revenue composition is as follows: 75.24% from product sales, 15.37% from commissioned processing services, 7.94% from licensing services, and 1.44% from leasing services [1] Fund Holdings - According to data from the top ten holdings of funds, one fund under Jiao Yin Schroder has a significant position in Sangfor Technologies. The Jiao Yin Medical Innovation Stock A (004075) reduced its holdings by 786,100 shares, retaining 1,584,300 shares, which accounts for 3.31% of the fund's net value, ranking it as the tenth largest holding [2] - The Jiao Yin Medical Innovation Stock A (004075) was established on March 23, 2017, with a latest scale of 2.5 billion CNY. Year-to-date returns are 40.18%, ranking 359 out of 4222 in its category; over the past year, returns are 46.72%, ranking 1679 out of 3795; since inception, returns have reached 200.36% [2] - The fund manager, Lou Huiyuan, has been in the position for 6 years and 361 days, with total assets under management of 4.04 billion CNY. The best fund return during this period is 160.35%, while the worst is -21.93% [2]

Core Viewpoint - The article discusses the upcoming 2025 Shanghai Leading Industries and the 14th Pharmaceutical CEO Forum, highlighting the focus on innovation and global expansion of Chinese pharmaceutical companies [1]. Summary by Sections Event Overview - The event will take place on September 4-5, 2025, at the Mandarin Oriental Hotel in Pudong, Shanghai, featuring nearly a hundred executives from listed companies, including chairpersons, CEOs, and industry leaders [4]. Morning Sessions - The morning session on September 4 will include a keynote speech and several roundtable discussions focusing on topics such as the global expansion of Chinese pharmaceutical companies and the search for the next billion-dollar drug [4][5]. - Notable discussions will include: - "From Local Innovation to Global Leadership: The Era of Chinese Pharmaceutical Companies Going Abroad" [4]. - "The Birth of Big Drugs is the Future of Pharmaceuticals: Finding the Next Billion-Dollar Bomb" [4]. Afternoon Sessions - The afternoon will feature discussions on future disease areas and technologies worth exploring for pharmaceutical assets going abroad, as well as the new cycle of Chinese innovative drugs under global competition [5][6]. - Additional topics will cover advancements in drug development platforms and the emerging field of brain-machine interfaces [6]. TMT Forum - The TMT (Technology, Media, and Telecommunications) forum will also take place, discussing AI's impact on various industries, including gaming and healthcare [7][8]. - Key topics will include AI innovations in mobile internet ecosystems and the future of AI in healthcare [7]. Pharmaceutical Sub-Forum - The pharmaceutical sub-forum will address topics such as ADC technology exploration, probiotic delivery systems, and the future development paths of dual antibodies and XDC [8]. - Discussions will also focus on the integration of medical insurance and the innovative practices in building a multi-level medical security system in China [8].